Mr. Nelson has over 15 years of experience in the pharmaceutical and biotech field, working primarily in project management, clinical operations, regulatory affairs, and public finance. He brings a significant amount and variety of cross-functional experience working at small companies in late-stage drug development. Prior to Milestone Pharmaceuticals, Mr. Nelson was Vice President Program Management at Mateon Therapeutics, an orphan oncology-focused biotech company. Previously he was the head of Clinical Operations at Axsome Therapeutics, and was a key member of Chelsea Therapeutics Operations and Regulatory teams, being integral to the development and approval of Northera(TM). Prior to Chelsea Therapeutics, Mr. Nelson was a sell-side equity analyst at Ladenburg Thalmann covering biotech and CRO companies for four years, and he started his career in Operations and Business Development for the generic pharmaceutical company Cobalt Pharmaceuticals. Mr. Nelson graduated from Brandeis University in 2003.